AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19332193 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment (MED)
Number of subjects: 2201
Study 19332193 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress testing (performed in 598 patients)
Number of subjects: 2201
Study 19332193 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducible ischemia (among patients with stress testing)
Number of subjects: 2201
Study 16970535 — intervention group
Group type: EXPERIMENTAL
Intervention: Semistandardized acupuncture (12 sessions, at least six local and two distant points needled bilaterally from a selection of predefined points)
Number of subjects: 301
Study 16970535 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture (superficial needling of at least 6 of 10 predefined, bilateral, distant nonacupuncture points)
Number of subjects: 301
Study 16970535 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (2 months no acupuncture followed by semistandardized acupuncture)
Number of subjects: 301
Study 12867204 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 days of free treatment coupon
Number of subjects: 577
Study 12867204 — intervention group
Group type: COMPARATOR
Intervention: Required to pay for treatment
Number of subjects: 577
Study 11182626 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet GP IIb/IIIa receptor antagonists (abciximab, eptifibatide, tirofiban, lamifiban)
Number of subjects: 33000
Study 11182626 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet GP IIb/IIIa receptor antagonists
Number of subjects: 33000
Study 11182626 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 33000
Study 9430504 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaine (B)
Number of subjects: 34
Study 9430504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A)
Number of subjects: 34
Study 8302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 30
Study 8302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 30
Study 8302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Zolpidem
Number of subjects: 30
Study 8302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Flunitrazepam
Number of subjects: 30
Study 8302193 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of both drugs
Number of subjects: 30
Study 3248317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon and acyclovir or descyclovir (n = 25)
Number of subjects: 146
Study 3248317 — intervention group
Group type: COMPARATOR
Intervention: Interferon treatment alone (n = 10)
Number of subjects: 146
Study 3248317 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir alone (n = 11)
Number of subjects: 146
Study 3248317 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 18)
Number of subjects: 146
Study 31595825 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed-goal group
Number of subjects: 80
Study 31595825 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-goal group
Number of subjects: 80
Study 28398091 — intervention group
Group type: EXPERIMENTAL
Intervention: Downward social comparison photos and descriptive norms information
Number of subjects: 223
Study 28398091 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward social comparison photos and descriptive norms information
Number of subjects: 223
Study 28398091 — intervention group
Group type: EXPERIMENTAL
Intervention: No comparison photos and descriptive norms information
Number of subjects: 223
Study 28398091 — intervention group
Group type: EXPERIMENTAL
Intervention: No photo and no comparison photos
Number of subjects: 223
Study 28398091 — intervention group
Group type: COMPARATOR
Intervention: No descriptive norms information
Number of subjects: 223
Study 28604014 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing treatment for depression
Number of subjects: 0
Study 28604014 — intervention group
Group type: COMPARATOR
Intervention: In-office treatment for depression
Number of subjects: 0
Study 26632754 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (LC) diet (14% energy as carbohydrate [CHO < 50 g/day], 28% protein [PRO], 58% fat [<10% saturated fat])
Number of subjects: 115
Study 26632754 — intervention group
Group type: COMPARATOR
Intervention: High Carbohydrate (HC) diet (53% CHO, 17% PRO, 30% fat [<10% saturated fat])
Number of subjects: 115
Study 23183781 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Kids program (n=728), 5 activity modules by mail at 4-week intervals
Number of subjects: 1398
Study 23183781 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=750), fact-based intervention only
Number of subjects: 1398
Study 21392685 — intervention group
Group type: EXPERIMENTAL
Intervention: Double extraction (deciduous canine and first molar)
Number of subjects: 68
Study 21392685 — intervention group
Group type: EXPERIMENTAL
Intervention: Single extraction (1 deciduous canine)
Number of subjects: 68
Study 21392685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 68
Study 18924386 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 0
Study 18924386 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 16570132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tränkmann's jumping-the-bite appliance (JTB)
Number of subjects: 2
Study 16570132 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 2
Study 16570132 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of treated groups (pre-pubertal vs pubertal)
Number of subjects: 2
Study 14577360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin orally 4 x 500 mg for 5 consecutive days
Number of subjects: 172
Study 14577360 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin orally 4 x 500 mg plus Gentamycin 2 x 80 mg i.m. for 3 to 5 days postoperatively
Number of subjects: 172
Study 14577360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 x 2 g i.v. Cefazolin intraoperatively and 24 hours following the manipulation
Number of subjects: 172
Study 14577360 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 172
Study 11319569 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release diltiazem (diltiazem CR)
Number of subjects: 20
Study 11319569 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release nifedipine (nifedipine SR)
Number of subjects: 20
Study 8855623 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha plus retinoic acid concomitant with standard radiotherapy
Number of subjects: 0
Study 8855623 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy
Number of subjects: 0
Study 1290959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole prophylaxis
Number of subjects: 0
Study 1290959 — intervention group
Group type: COMPARATOR
Intervention: Empiric amphotericin B
Number of subjects: 0
Study 6318170 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg)
Number of subjects: 43
Study 6318170 — intervention group
Group type: EXPERIMENTAL
Intervention: Depo-medroxyprogesterone acetate (DMPA) (150 mg intramuscular injection)
Number of subjects: 43
Study 6318170 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens
Number of subjects: 43
Study 6318170 — intervention group
Group type: COMPARATOR
Intervention: Depo-medroxyprogesterone acetate (DMPA)
Number of subjects: 43
Study 6318170 — intervention group
Group type: COMPARATOR
Intervention: Conjugated estrogens and DMPA
Number of subjects: 43
Study 31175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram followed by venlafaxine
Number of subjects: 20
Study 31175352 — intervention group
Group type: COMPARATOR
Intervention: Remitted patients (control group)
Number of subjects: 20
Study 31175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients
Number of subjects: 20
Study 31175352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remitting vs nonremitting acute patients
Number of subjects: 20
Study 29534210 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on the Future intervention (single-session, clinic-based)
Number of subjects: 394
Study 27198039 — intervention group
Group type: EXPERIMENTAL
Intervention: Curanderismo treatment (33 sessions over 10 months)
Number of subjects: 1
Study 27198039 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 1
Study 24627538 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 47
Study 24627538 — intervention group
Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 47
Study 21088046 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (2 nights)
Number of subjects: 32
Study 21088046 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid eye movement sleep deprivation (4 nights)
Number of subjects: 32
Study 21088046 — intervention group
Group type: COMPARATOR
Intervention: Control (regular nights of sleep)
Number of subjects: 32
Study 21097420 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous rocuronium infusion
Number of subjects: 40
Study 21097420 — intervention group
Group type: COMPARATOR
Intervention: No supplemental muscle relaxants (Group A)
Number of subjects: 40
Study 17916229 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (25 mg q.d.)
Number of subjects: 40
Study 17916229 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg b.i.d.)
Number of subjects: 40
Study 17916229 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.i.d.)
Number of subjects: 40
Study 17916229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16123370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 54
Study 16123370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 12201356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplement (two tablets daily)
Number of subjects: 168
Study 12201356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 10444118 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg intranasal desmopressin
Number of subjects: 20
Study 10444118 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg intranasal desmopressin
Number of subjects: 20
Study 10444118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7774832 — intervention group
Group type: COMPARATOR
Intervention: CAP (cyclophosphamide‐doxorubicin‐cisplatin)
Number of subjects: 196
Study 7774832 — intervention group
Group type: EXPERIMENTAL
Intervention: SRCA-guided chemotherapy
Number of subjects: 196
Study 7774832 — intervention group
Group type: EXPERIMENTAL
Intervention: CACAR (cyclophosphamide‐doxorubicin‐carboplatin)
Number of subjects: 196
Study 7774832 — intervention group
Group type: EXPERIMENTAL
Intervention: SRCA-CAP
Number of subjects: 196
Study 7774832 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (guided by SRCA)
Number of subjects: 196
Study 7774832 — intervention group
Group type: COMPARATOR
Intervention: CAP (not guided by SRCA)
Number of subjects: 196
Study 7774832 — intervention group
Group type: EXPERIMENTAL
Intervention: SRCA arm
Number of subjects: 196
Study 7774832 — intervention group
Group type: COMPARATOR
Intervention: CAP arm
Number of subjects: 196
Study 2317911 — intervention group
Group type: COMPARATOR
Intervention: Exercise without calorie restriction (n = 46)
Number of subjects: 130
Study 2317911 — intervention group
Group type: COMPARATOR
Intervention: Calorie restriction without exercise (n = 42)
Number of subjects: 130
Study 2317911 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (n = 42)
Number of subjects: 130
Study 7028257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (50 mg/m²) every 3 weeks (Group 1)
Number of subjects: 50
Study 7028257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (100 mg/m²) every 3 weeks (Group 2)
Number of subjects: 50
Study 31899570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (2 mg/kg)
Number of subjects: 12
Study 31899570 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (2.2 mg/kg)
Number of subjects: 12
Study 31899570 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 31410902 — intervention group
Group type: COMPARATOR
Intervention: High confidence in negative shedding status
Number of subjects: 11061
Study 31410902 — intervention group
Group type: COMPARATOR
Intervention: Potential for misclassification of shedding status
Number of subjects: 11061
Study 31410902 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 11061
Study 28683806 — intervention group
Group type: EXPERIMENTAL
Intervention: HMS BAB training intervention (one-day competency-based training followed by 8 weeks of peer-based practice)
Number of subjects: 38
Study 28683806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 38
Study 25938834 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (experimental group; n=114)
Number of subjects: 216
Study 25938834 — intervention group
Group type: COMPARATOR
Intervention: Glutathione (control group; n=102)
Number of subjects: 216
Study 25938834 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium isoglycyrrhizinate (experimental group)
Number of subjects: 216
Study 24075073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 29
Study 24075073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 21849241 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation (EAS) at GB37
Number of subjects: 28
Study 21849241 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation (EAS) at KI8
Number of subjects: 28
Study 19680668 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1/200,000 epinephrine
Number of subjects: 60
Study 19680668 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 17509880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 17509880 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 0
Study 17509880 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil (EPO)
Number of subjects: 0
Study 17509880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 15226210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (Guidant Galileo System)
Number of subjects: 27
Study 15226210 — intervention group
Group type: COMPARATOR
Intervention: Control (Coronary stenting)
Number of subjects: 27
Study 15226210 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference vessel
Number of subjects: 27
Study 15226210 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 27
Study 11810791 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antihypertensive drugs (ACE inhibitors, calcium antagonists, alpha-blockers)
Number of subjects: 58000
Study 11810791 — intervention group
Group type: COMPARATOR
Intervention: Older antihypertensive drugs (thiazide diuretics, beta-blockers)
Number of subjects: 58000
Study 9773792 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD children
Number of subjects: 189
Study 9773792 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD children with severe renal cystic disease (> 10 cysts)
Number of subjects: 189
Study 9773792 — intervention group
Group type: EXPERIMENTAL
Intervention: ADPKD children diagnosed after the first year of life
Number of subjects: 189
Study 7940328 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraarticular injection of triamcinolone acetonide +/‐ cyclophosphamide
Number of subjects: 112
Study 7940328 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intraarticular injection of glucocorticosteroids (methylprednisolone acetate, triamcinolone acetonide, composition with cyclophosphamide and dimethylsulfoxide)
Number of subjects: 112
Study 3063286 — intervention group
Group type: EXPERIMENTAL
Intervention: captopril (75 mg/d)
Number of subjects: 30
Study 3063286 — intervention group
Group type: EXPERIMENTAL
Intervention: canrenoate potassium (200 mg/d)
Number of subjects: 30
Study 3063286 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (100 mg/d)
Number of subjects: 30
Study 31936727 — intervention group
Group type: EXPERIMENTAL
Intervention: CrM-HMB group (0.04 g/kg/day of CrM plus 3 g/day of HMB)
Number of subjects: 28
Study 31936727 — intervention group
Group type: EXPERIMENTAL
Intervention: CrM-HMB group
Number of subjects: 28
Study 31936727 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PLG)
Number of subjects: 28
Study 31936727 — intervention group
Group type: COMPARATOR
Intervention: CrM group (0.04 g/kg/day of CrM)
Number of subjects: 28
Study 31936727 — intervention group
Group type: COMPARATOR
Intervention: HMB group (3 g/day of HMB)
Number of subjects: 28
Study 29531290 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime ingestion of hypertension medications (n=1037)
Number of subjects: 2078
Study 29531290 — intervention group
Group type: COMPARATOR
Intervention: Morning ingestion of hypertension medications (n=1041)
Number of subjects: 2078
Study 27365521 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care (teeth surface cleaning, scaling, and tongue cleaning weekly for 8 weeks)
Number of subjects: 200
Study 27365521 — intervention group
Group type: COMPARATOR
Intervention: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Number of subjects: 200
Study 25040447 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial education and support programme plus nicotine replacement therapy (NRT) for 8 weeks
Number of subjects: 1046
Study 25040447 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) for 8 weeks plus Quitline support
Number of subjects: 1046
Study 22936100 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation of a recent target after fixating on a target (cricket ball) among semantically related distracters in Experiment 1.
Number of subjects: 0
Study 22936100 — intervention group
Group type: EXPERIMENTAL
Intervention: Using silhouettes of objects for selection based on feature shape in Experiment 2.
Number of subjects: 0
Study 22936100 — intervention group
Group type: EXPERIMENTAL
Intervention: Using silhouettes of animals with distracters of low target-shape similarity in Experiment 3.
Number of subjects: 0
Study 22936100 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducing a distracter with the target in the probe display in Experiments 4 and 5.
Number of subjects: 0
Study 21197854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (5.0 mg caffeine/kg bodyweight)
Number of subjects: 8
Study 21197854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-free energy drink
Number of subjects: 8
Study 21197854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21197854 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink
Number of subjects: 8
Study 18451643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated membrane (VE)
Number of subjects: 62
Study 18451643 — intervention group
Group type: COMPARATOR
Intervention: Reference polysulfone (PS) membrane
Number of subjects: 62
Study 16758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin (low molecular-weight heparin) administered before surgery
Number of subjects: 152
Study 16758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Fraxiparin (low molecular-weight heparin) administered after surgery
Number of subjects: 152
Study 16758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 152
Study 16758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative preventive treatment with Fraxiparin
Number of subjects: 152
Study 16758942 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis prolonged for at least one month
Number of subjects: 152
Study 12676037 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual postoperative care plus massage therapy
Number of subjects: 105
Study 12676037 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual postoperative care plus vibration therapy
Number of subjects: 105
Study 12676037 — intervention group
Group type: COMPARATOR
Intervention: Usual postoperative care (UC)
Number of subjects: 105
Study 11104859 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal problem-solving remediation
Number of subjects: 28
Study 11104859 — intervention group
Group type: COMPARATOR
Intervention: Placebo instruction
Number of subjects: 28
Study 9175116 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP-1 alpha positive glial cells in white matter
Number of subjects: 13
Study 9175116 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP-1 alpha positive neurons and glial cells in cortex
Number of subjects: 13
Study 9175116 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP-1 alpha mRNA expression
Number of subjects: 13
Study 7967328 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin (165 mg once daily)
Number of subjects: 94
Study 7967328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of heparin (1,000 units per hour)
Number of subjects: 94
Study 7967328 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 94
Study 3981166 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dose of metoprolol
Number of subjects: 0
Study 3981166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30057059 — intervention group
Group type: EXPERIMENTAL
Intervention: Laughter Yoga (LY)
Number of subjects: 120
Study 30057059 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedy Movie (spontaneous laughter)
Number of subjects: 120
Study 30057059 — intervention group
Group type: COMPARATOR
Intervention: Reading a Book
Number of subjects: 120
Study 27018419 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 250 mg
Number of subjects: 59
Study 27018419 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine citrate 76 mg
Number of subjects: 59
Study 27018419 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 59